Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Foamix Pharmaceuticals Ltd.
DescriptionTopical foam formulation of 4% doxycycline
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard Indication Dermatology (unspecified)
Indication DetailsPrevent moderate to severe skin rashes in cancer patients treated with EGFR inhibitors; Treat chemotherapy-induced rash
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today